JP2019511533A - 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 - Google Patents

小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 Download PDF

Info

Publication number
JP2019511533A
JP2019511533A JP2018553428A JP2018553428A JP2019511533A JP 2019511533 A JP2019511533 A JP 2019511533A JP 2018553428 A JP2018553428 A JP 2018553428A JP 2018553428 A JP2018553428 A JP 2018553428A JP 2019511533 A JP2019511533 A JP 2019511533A
Authority
JP
Japan
Prior art keywords
dengue
virus
seq
tdv
pfu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2018553428A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019511533A5 (enExample
Inventor
ウォレス、デレク
ボスレゴ、ジョン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Vaccines Inc
Original Assignee
Takeda Vaccines Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Inc filed Critical Takeda Vaccines Inc
Publication of JP2019511533A publication Critical patent/JP2019511533A/ja
Publication of JP2019511533A5 publication Critical patent/JP2019511533A5/ja
Priority to JP2022069423A priority Critical patent/JP2022089964A/ja
Priority to JP2024044760A priority patent/JP2024071463A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material
    • C12N2770/24152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161—Methods of inactivation or attenuation
    • C12N2770/24164—Methods of inactivation or attenuation by serial passage
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24171—Demonstrated in vivo effect
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2018553428A 2016-04-13 2017-04-13 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法 Pending JP2019511533A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022069423A JP2022089964A (ja) 2016-04-13 2022-04-20 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
JP2024044760A JP2024071463A (ja) 2016-04-13 2024-03-21 小児及び若年成人のデングウイルスに対するワクチンの組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662322167P 2016-04-13 2016-04-13
US62/322,167 2016-04-13
PCT/IB2017/052160 WO2017179017A1 (en) 2016-04-13 2017-04-13 Compositions and methods of vaccination against dengue virus in children and young adults

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022069423A Division JP2022089964A (ja) 2016-04-13 2022-04-20 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法

Publications (2)

Publication Number Publication Date
JP2019511533A true JP2019511533A (ja) 2019-04-25
JP2019511533A5 JP2019511533A5 (enExample) 2020-05-14

Family

ID=58671740

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2018553428A Pending JP2019511533A (ja) 2016-04-13 2017-04-13 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
JP2022069423A Pending JP2022089964A (ja) 2016-04-13 2022-04-20 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
JP2024044760A Withdrawn JP2024071463A (ja) 2016-04-13 2024-03-21 小児及び若年成人のデングウイルスに対するワクチンの組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022069423A Pending JP2022089964A (ja) 2016-04-13 2022-04-20 小児及び若年成人のデングウイルスに対するワクチンの組成物及び方法
JP2024044760A Withdrawn JP2024071463A (ja) 2016-04-13 2024-03-21 小児及び若年成人のデングウイルスに対するワクチンの組成物

Country Status (14)

Country Link
US (3) US11007261B2 (enExample)
EP (1) EP3442571A1 (enExample)
JP (3) JP2019511533A (enExample)
KR (1) KR102611235B1 (enExample)
CN (2) CN120392993A (enExample)
AU (2) AU2017250696A1 (enExample)
BR (1) BR112018071087A2 (enExample)
CA (1) CA3020484A1 (enExample)
CO (1) CO2018011355A2 (enExample)
MX (1) MX2018012459A (enExample)
MY (1) MY192806A (enExample)
PH (1) PH12018502175B1 (enExample)
SG (2) SG10201913383RA (enExample)
WO (1) WO2017179017A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521391A (ja) * 2020-04-09 2023-05-24 タケダ ワクチン，インコーポレイテッド 複合試料における単一ウイルスハプロタイプの定性的及び定量的な決定

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102389908B1 (ko) 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
KR102611235B1 (ko) * 2016-04-13 2023-12-08 다케다 백신즈 인코포레이티드 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
TW202309276A (zh) 2016-08-03 2023-03-01 美商武田疫苗股份有限公司 用於與經改良之調配物一起穩定黃病毒的組成物及方法
CN111447947B (zh) * 2017-12-07 2024-01-12 默沙东有限责任公司 登革病毒疫苗组合物的制剂
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
ES2908304T3 (es) * 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
PH12022550261A1 (en) * 2019-08-16 2023-06-26 Takeda Vaccines Inc Methods for preventing dengue and hepatitis a
WO2021174059A1 (en) 2020-02-27 2021-09-02 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
WO2023147337A2 (en) 2022-01-25 2023-08-03 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
US20250177511A1 (en) 2022-02-15 2025-06-05 Takeda Vaccines, Inc. Dengue vaccine batch mixing process
WO2023215383A1 (en) 2022-05-04 2023-11-09 Takeda Vaccines, Inc. Computer-based determination of flavivirus infectivity
WO2024086681A1 (en) * 2022-10-20 2024-04-25 Takeda Vaccines, Inc. A method for detecting the presence of a dengue virus serotype in a sample containing at least one dengue virus serotype
EP4612495A1 (en) * 2022-11-02 2025-09-10 Takeda Vaccines, Inc. A method for determining the infectivity of a virus
EP4375381A1 (en) 2022-11-18 2024-05-29 Takeda Vaccines, Inc. A method for determining the proportion of a live, attenuated flavivirus having a nucleotide sequence comprising at least one attenuation locus in a formulation
EP4626574A1 (en) 2022-11-29 2025-10-08 Takeda Vaccines, Inc. Large-scale flaviviral vaccine production and manufacture
WO2025122855A1 (en) 2023-12-08 2025-06-12 Takeda Vaccines, Inc. A method for determining the concentration of residual vero cell genomic dna in a sample containing virus obtained from production in vero cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520196A (ja) * 2012-06-10 2015-07-16 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対するワクチン投与のための組成物および方法
JP2015524421A (ja) * 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
JP2016501015A (ja) * 2012-11-08 2016-01-18 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルス血清型４構築物に関する組成物、方法および使用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2338508T (pt) * 2002-05-03 2018-05-16 The Government Of The Us Secretary Department Of Health And Human Services Vírus da dengue quimérico recombinante rden3/4delta30(me), rden2/4delta30(me) ou rden1/4delta30(me) contendo uma deleção de 30 nucleótidos (delta30) numa secção da região não traduzida a 3¿ do genoma da dengue de tipo 4, em que a referida deleção de 30 nucleótidos corresponde à estrutura em gancho de cabelo tl2
CN102449172A (zh) 2009-06-01 2012-05-09 伊维拉根公司 施用针对登革病毒的疫苗的组合物和方法
US8968996B2 (en) * 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
SG11201401733VA (en) * 2011-10-25 2014-09-26 Florida Gulf Coast University Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes
WO2014093182A1 (en) 2012-12-14 2014-06-19 Inviragen, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
KR102389908B1 (ko) * 2013-03-15 2022-04-26 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
KR102611235B1 (ko) * 2016-04-13 2023-12-08 다케다 백신즈 인코포레이티드 어린이 및 젊은 성인에서 뎅기 바이러스에 대한 백신접종 조성물 및 방법
ES2908304T3 (es) * 2018-09-05 2022-04-28 Takeda Vaccines Inc Dosis unitaria de vacuna contra el dengue y administración de la misma
US11464815B2 (en) * 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015520196A (ja) * 2012-06-10 2015-07-16 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルスに対するワクチン投与のための組成物および方法
JP2015524421A (ja) * 2012-07-24 2015-08-24 サノフィ・パスツールＳａｎｏｆｉｐａｓｔｅｕｒ ワクチン組成物
JP2016501015A (ja) * 2012-11-08 2016-01-18 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. デングウイルス血清型４構築物に関する組成物、方法および使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023521391A (ja) * 2020-04-09 2023-05-24 タケダ ワクチン，インコーポレイテッド 複合試料における単一ウイルスハプロタイプの定性的及び定量的な決定

Also Published As

Publication number Publication date
MY192806A (en) 2022-09-09
CA3020484A1 (en) 2017-10-19
PH12018502175B1 (en) 2023-12-06
US11007261B2 (en) 2021-05-18
US20190381163A1 (en) 2019-12-19
MX2018012459A (es) 2019-06-06
US20250235522A1 (en) 2025-07-24
KR20180137514A (ko) 2018-12-27
EP3442571A1 (en) 2019-02-20
SG10201913383RA (en) 2020-03-30
SG11201808906RA (en) 2018-11-29
AU2018267542A1 (en) 2018-12-13
CN120392993A (zh) 2025-08-01
WO2017179017A1 (en) 2017-10-19
BR112018071087A2 (pt) 2019-02-26
US20210236620A1 (en) 2021-08-05
KR102611235B1 (ko) 2023-12-08
CO2018011355A2 (es) 2018-11-13
AU2017250696A1 (en) 2018-11-22
CN109069615B (zh) 2025-03-04
AU2018267542B2 (en) 2020-06-18
JP2024071463A (ja) 2024-05-24
CN109069615A (zh) 2018-12-21
PH12018502175A1 (en) 2019-10-28
JP2022089964A (ja) 2022-06-16

Similar Documents

Publication Publication Date Title
US20250235522A1 (en) Compositions and methods of vaccination against dengue virus in children and young adults
US11931399B2 (en) Compositions and methods for dengue virus chimeric constructions in vaccines
HK40014417B (en) Compositions and methods for dengue virus chimeric constructs in vaccines
BR112015023635B1 (pt) Moléculas de polinucleotídeo que codificam uma cepa pdk-53 modificada do vírus dengue-2 vivo atenuado, cepa pdk-53 do vírus vivo atenuado dengue 2 modificada, polipeptídeos, vetor, composição farmacêutica, uso da mesma, composição imunogênica e kit
NZ735336B2 (en) Compositions and methods for dengue virus chimeric constructs in vaccines
HK1220359B (en) Compositions and methods for dengue virus chimeric constructs in vaccines

Legal Events

Date Code Title Description
A529 Written submission of copy of amendment under article 34 pct

Free format text: JAPANESE INTERMEDIATE CODE: A529

Effective date: 20181030

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200406

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210427

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210727

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210908

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211221